Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA; Alliance for Clinical Trials in Oncology. Dueck AC, et al. Among authors: perez ea. Osteoporos Int. 2015 Jul;26(7):1971-7. doi: 10.1007/s00198-015-3091-4. Epub 2015 Mar 7. Osteoporos Int. 2015. PMID: 25749740 Free PMC article. Clinical Trial.
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. Perez EA, et al. Ann Oncol. 2010 Feb;21(2):269-274. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9. Ann Oncol. 2010. PMID: 19901014 Free PMC article. Clinical Trial.
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. Tan WW, et al. Among authors: perez ea. Ann Oncol. 2013 Oct;24(10):2548-2554. doi: 10.1093/annonc/mdt213. Epub 2013 Jun 24. Ann Oncol. 2013. PMID: 23798616 Free PMC article. Clinical Trial.
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. Cheng H, et al. Among authors: perez ea. Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12. Br J Cancer. 2014. PMID: 25117817 Free PMC article. Clinical Trial.
627 results